For monitoring skeletal effects of the antiresorption treatments it is advantageous to employ techniques aimed to a quantitative assessment of specific aspects of quality of bone that respond most significantly to the treatment and best reflect the mechanisms of action of the drug. It is recommended to employ surrogates of risk of fracture, such as measurement bone mineral density using dual X-ray absorptiometry and assessment of bone resorption using biochemical markers. Monitoring enables to identify patients not responding to the treatment or are not adherent to treatments. The information provided by bone mineral density may be further elaborated using the biochemical markers. The Least Significant Change enables an appropriate clinical interpretation of the measurements.

        Key words: bone minerál, bone markers, monitoring, quality of bone